<DOC>
	<DOCNO>NCT02784613</DOCNO>
	<brief_summary>This unblinded study conduct single research center , San Diego Sexual Medicine . Subjects meet inclusion exclusion criterion receive 60 mg ospemifene daily twenty week . After informed consent sign , baseline physical examination , vulvoscopy detail photography vulva , vestibule vagina , perform . Physical examination vulvoscopy detail photography vulva , vestibule vagina , repeat prospectively every 4 week total 20 week . Therefore , physical examination vulvoscopy detail photography vulva , vestibule vagina perform prospectively baseline ( vulvoscopy session 1 ) , 4 week ( vulvoscopy session 2 ) , 8 week ( vulvoscopy session 3 ) , 12 , week ( vulvoscopy session 4 ) , 16 week ( vulvoscopy session 5 ) 20 week ( vulvoscopy session 6 ) follow daily administration 60 mg ospemifene .</brief_summary>
	<brief_title>Vulvoscopy Changes Vulva , Vestibule Vagina With Daily Ospemifene Women With Dyspareunia From VVA</brief_title>
	<detailed_description>Ospemifene indicate post-menopausal woman diagnose vulvar vaginal atrophy ( VVA ) dyspareunia . While ospemifene clinically significantly reduce pain associate dyspareunia , little prospective documentation use vulvoscopy detail photography visible change vulva , vestibule vaginal region daily administration 60 mg ospemifene post-menopausal woman VVA dyspareunia . This study include total 6 prospective photographic session vulva , vestibule vagina 20 week administration 60 mg ospemifene study . Comparisons make baseline photography ( vulvoscopy session 0 ) photography 4 week ( vulvoscopy session 1 ) , 8 week ( vulvoscopy session 2 ) , 12 week ( vulvoscopy session 3 ) , 16 week ( vulvoscopy session 4 ) 20 week ( vulvoscopy session 5 ) . Currently limited prospective study use vulvoscopy detail photography demonstrate visible change vulva , vestibule vagina follow oral administration 60 mg ospemifene post-menopausal woman VVA dyspareunia . Information regard visible change vulva , vestibule vagina may important patient health care provider best understand beneficial effect ospemifene ensure patient compliance treatment .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . Subject provide write informed consent HIPAA authorization study procedure conduct 2 . Subject female 3 . Subject age 2180 year 4 . Subject body mass index ( BMI ) &lt; 37 kg/m2 5 . Subject menopausal either naturally ( least 12 month amenorrheic ) 6 week bilateral salpingooophorectomy prior natural menopause subject hysterectomy must serum FSH &gt; 40 mIU/mL 6 . Subject vulvovaginal atrophy dyspareunia 7 . Subject normal mammogram within last 6 month 8 . Subject normal pap smear within last 6 month 9 . Subject endometrial stripe â‰¤ 4 mm within last 6 month uterus 10 . Subject agree comply study procedures visit . 1 . Subject hypersensitivity ingredient ospemifene 2 . Subject use ospemifene past 3 . Subject document suspected breast cancer , history heart attack stroke 4 . Subject clinically significant finding physical examination 5 . Subject uncontrolled hypertension 6 . Subject chronic medical condition psychologic disorder Principal Investigator feel make ineligible study 7 . Subject currently local systemic androgen therapy include local systemic testosterone ( washout 14 day local topical androgen nondepot injection , 1 month depot , 6 month pellet 8 . Subject currently local systemic estrogen therapy androgen therapy ( washout 14 day vaginal estrogen , 60 day oral/transdermal therapy ) 9 . Subject currently use SERM product estrogenic antiestrogenic effect within last month 10 . Subject currently use itraconazole , ketoconazole , digitalis alkaloid heparin strong cytochrome P 450 3A4 inhibitor 11 . Subject history substance abuse within 12 month prior , consume &gt; 14 alcoholic drink per week 12 . Subject receive investigational drug within 30 day prior sign consent 13 . Subject condition exhibit behavior indicate Principal Investigator Subject unlikely compliant study procedures visit .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>